Working… Menu
Trial record 1 of 9 for:    zw25
Previous Study | Return to List | Next Study

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04224272
Recruitment Status : Recruiting
First Posted : January 13, 2020
Last Update Posted : June 21, 2021
Information provided by (Responsible Party):
Zymeworks Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 30, 2022
Estimated Study Completion Date : June 30, 2023